J Gynecol Oncol.  2012 Apr;23(2):86-90. 10.3802/jgo.2012.23.2.86.

Thrombopoietin: a novel candidate tumor marker for the diagnosis of ovarian cancer

• Mermer T
• Terek MC
• Zeybek B
• Ergenoglu
• Yeniel AO
• Ozsaran A
• Zekioglu O

• KMID: 2177580
• DOI: http://doi.org/10.3802/jgo.2012.23.2.86

Abstract

OBJECTIVE
To investigate the decisive role of preoperative serum thrombopoietin levels in the discrimination of benign and malignant ovarian pathologies and its value in the evaluation of treatment response.
METHODS
Fifty patients with diagnoses of adnexal masses (25 benign, 25 malignant) were included in the study. Blood samples were collected from all cases preoperatively. Age, menopausal status, adnexal mass size, preoperative CA-125 level, platelet count, the stage of the disease (FIGO stage), tumor grade, histologic subgroup, the residual tumor mass, ascites cytology, surgical procedures, and postoperative treatments were recorded for the malignant group. Response to treatment was evaluated based on the revised RECIST guideline.
RESULTS
The preoperative serum thrombopoietin levels of the malignant cases (median, 98; range, 7 to 768) were significantly higher when compared with those of benign cases (median, 27; range, 13 to 131; p=0.004). The positive predictive value of CA-125 was found to be 79%, when it was used as a single marker; however it had risen to 85% when both CA-125 and thrombopoietin levels were used. There was no significant relationship between preoperative serum thrombopoietin levels and tumor grade, ascites cytology, presence of residual mass, and response to treatment. The preoperative serum thrombopoietin levels were significantly higher in stage III-IV cases and cases with serous histology. The post-treatment serum thrombopoietin levels in the malignant group were significantly lower as compared with the preoperative thrombopoietin levels.
CONCLUSION
Thrombopoietin can play an additive role for prediction of ovarian cancer.

Keyword

Biological tumor markers; Ovarian neoplasms; Thrombopoietin

MeSH Terms

Ascites
Discrimination (Psychology)
Humans
Neoplasm, Residual
Ovarian Neoplasms
Platelet Count
Thrombopoietin
Biomarkers, Tumor
Thrombopoietin

Reference

1. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst. 2005. 97:1407–1427.

2. Ries LA, Harkins D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, et al. SEER cancer statistics review, 1975-2003. 2005. Bethesda, MD: National Cancer Institute.

3. Bell R, Petticrew M, Sheldon T. The performance of screening tests for ovarian cancer: results of a systematic review. Br J Obstet Gynaecol. 1998. 105:1136–1147.

4. Markman M. The role of CA-125 in the management of ovarian cancer. Oncologist. 1997. 2:6–9.

5. Buys SS, Partridge E, Greene MH, Prorok PC, Reding D, Riley TL, et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol. 2005. 193:1630–1639.

6. Rapkiewicz AV, Espina V, Petricoin EF 3rd, Liotta LA. Biomarkers of ovarian tumours. Eur J Cancer. 2004. 40:2604–2612.

7. Dupont J, Tanwar MK, Thaler HT, Fleisher M, Kauff N, Hensley ML, et al. Early detection and prognosis of ovarian cancer using serum YKL-40. J Clin Oncol. 2004. 22:3330–3339.

8. de Sauvage FJ, Hass PE, Spencer SD, Malloy BE, Gurney AL, Spencer SA, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature. 1994. 369:533–538.

9. Furuhashi M, Miyabe Y, Oda H. A case of thrombopoietin-producing ovarian carcinoma confirmed by immunohistochemistry. Gynecol Oncol. 1999. 74:278–281.

10. Komura E, Matsumura T, Kato T, Tahara T, Tsunoda Y, Sawada T. Thrombopoietin in patients with hepatoblastoma. Stem Cells. 1998. 16:329–333.

11. Ryu T, Nishimura S, Miura H, Yamada H, Morita H, Miyazaki H, et al. Thrombopoietin-producing hepatocellular carcinoma. Intern Med. 2003. 42:730–734.

12. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009. 45:228–247.

13. Torres MP, Ponnusamy MP, Lakshmanan I, Batra SK. Immunopathogenesis of ovarian cancer. Minerva Med. 2009. 100:385–400.

14. Chambers SK. Role of CSF-1 in progression of epithelial ovarian cancer. Future Oncol. 2009. 5:1429–1440.

15. Nowak M, Glowacka E, Szpakowski M, Szyllo K, Malinowski A, Kulig A, et al. Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors. Neuro Endocrinol Lett. 2010. 31:375–383.

16. Tsukishiro S, Suzumori N, Nishikawa H, Arakawa A, Suzumori K. Preoperative serum thrombopoietin levels are higher in patients with ovarian cancer than with benign cysts. Eur J Obstet Gynecol Reprod Biol. 2008. 140:67–70.